Advances and challenges in hereditary cancer pharmacogenetics.

@article{Cascorbi2017AdvancesAC,
  title={Advances and challenges in hereditary cancer pharmacogenetics.},
  author={Ingolf Cascorbi and Anneke Nina Werk},
  journal={Expert opinion on drug metabolism & toxicology},
  year={2017},
  volume={13 1},
  pages={73-82}
}
INTRODUCTION Cancer pharmacogenetics usually considers tumor-specific targets. However, hereditary genetic variants may interfere with the pharmacokinetics of antimetabolites and other anti-cancer drugs, which may lead to severe adverse events. Areas covered: Here, the impact of hereditary genes considered in drug labels such as thiopurine S-methyltransferase (TPMT), UDP-glucuronosyltransferase 1A1 (UTG1A1) and dihydropyrimidine dehydrogenase (DPYD) are discussed with respect to guidelines of… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-3 of 3 extracted citations

Similar Papers

Loading similar papers…